Alltracel boosts Japanese firm's woundcare line:
This article was originally published in Clinica
Alltracel Pharmaceuticals has entered an agreement with Japanese consumer woundcare company Nichiban to develop and market Alltracel's m.doc "stop-bleeding" technology in Japan. The initial focus is to integrate the Dublin, Ireland-based company's SEAL.ON first aid treatment range, which incorporates m.doc's fast coagulating properties, into Nichiban's portfolio of woundcare brands. The Tokyo-based firm, which holds a 23% majority share of the Japanese consumer woundcare market, says it also plans to upgrade its own line-up of existing brands by introducing m.doc technology into the products.
You may also be interested in...
Infogram: OTC firms should start thinking about post-COVID-19 business strategy, SEMPORA Consulting GmbH suggests, based on a recent survey on the impact of the coronavirus on German OTC companies.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
With hospitals throughout the EU short of urgently needed COVID-19 medical supplies, including respiratory equipment, there are ways for companies to sell and deliver their products quickly.